Great Point Partners strikes deal for cell therapy CDMO
Newly acquired Performance Cell Manufacturing will now be known as Cellipont Bioservices
Performance Cell Manufacturing (PCM), a contract development and manufacturing organization (CDMO) that specializes in manufacturing cell therapies, has been purchased by Great Point Partners (GPP), a private investment firm focused on the healthcare industry. Per the deal, the PCM will now operate under a new name: Cellipont Bioservices.
This move is the latest among various CDMO investments made by GPP. The company has invested in other CDMOs, such as Cytovance Biologics, MaSTherCell, Tergus Pharma and Bionova Scientific.
“The Cellipont Bioservices team continues to demonstrate their ability to deliver for clients with an unwavering commitment to quality as its top priority. “Across their process development and manufacturing services, the team shares both scientific depth and a steadfast dedication to client service,” comments Noah Rhodes, managing director at Great Point Partners. “… We look forward to supporting the Cellipont team as it expands its offerings to help deliver promising new cell therapies to patients.”
Cellipont Bioservices’ board of directors has appointed Deborah Wild as president and CEO, and Will James as CFO. Carolyn Wrightson, who has served as COO for the predecessor company for more than 15 years, will continue in that role.
